Nonprofit Acquires Abandoned Leukemia Drug Supply.

Blood Cancer United secures remaining luveltamab tazevibulin supply to support children with rare AML, highlighting ongoing challenges in pediatric cancer drug funding.

• Why it matters: Addressing the gap in funding for pediatric cancer treatments is crucial, as many promising drugs remain inaccessible or abandoned due to financial constraints, limiting options for vulnerable patients.
• What they did: The nonprofit acquired the remaining stock of the leukemia drug and will sustain the compassionate use program, providing access to children with a rare AML subtype.
• The result: This effort enables continued treatment for affected children and underscores the importance of nonprofit initiatives in overcoming funding barriers in pediatric oncology.